Neurotech initiates Phase 1 clinical trial for AAD-2004

Published: 2010-09-03 06:56:00

Updated: 2010-09-03 06:56:00

Neurotech Pharmaceuticals said on August 30 that it has begun dosing in the Phase 1 clinical testing of AAD-2004, a potent spin trapping molecule and microsomal prostaglandin E synthase-1 inhibitor, targeting Alzheimer's, Parkinson's, and Lou Gehrig's Disease.

AAD-2004 was developed as a dual ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK